Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Public ClinicalTrials.gov record NCT05555732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT05555732
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,170 participants
Conditions and interventions
Conditions
Interventions
- Datopotamab Deruxtecan Drug
- Pembrolizumab Drug
- Pemetrexed Drug
- Carboplatin Drug
- Cisplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2023 (Actual)
- Primary completion
- May 11, 2029 (Estimated)
- Completion
- May 11, 2031 (Estimated)
- Last update posted
- Jun 23, 2026
2023 – 2031
United States locations
- U.S. sites
- 36
- U.S. states
- 14
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center Pc | Daphne | Alabama | 36526 | — |
| Ironwood Cancer and Research Centers | Chandler | Arizona | 85224 | — |
| Arizona Oncology Associates, Pc - Nahoa | Prescott Valley | Arizona | 86314 | — |
| Hoag Memorial Hospital Prebyterian | Newport Beach | California | 92663 | — |
| Compassionate Cancer Care Medical Group | Riverside | California | 92501 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Ronald Reagan UCLA Medical Center | Santa Monica | California | 90404 | — |
| UCHealth Memorial Hospital | Colorado Springs | Colorado | 80909 | — |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | — |
| Cancer Specialist of North Florida | Jacksonville | Florida | 32256 | — |
| Cancer Care Centers of Brevard, Inc. | Palm Bay | Florida | 32901 | — |
| Woodlands Medical Specialists, Pa | Pensacola | Florida | 32503 | — |
| Florida Cancer Specialists-North | St. Petersburg | Florida | 33705 | — |
| Emory University - Winship Cancer Institute Wci | Atlanta | Georgia | 30322-1013 | — |
| Illinois Cancer Specialists | Niles | Illinois | 60714 | — |
| American Oncology Partners of Maryland | Bethesda | Maryland | 20817 | — |
| Maryland Oncology Heamtology P.A. | Columbia | Maryland | 21044 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute; Inv Drg Svc Pharm | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute At St. Elizabeth'S Medical Center | Brighton | Massachusetts | 02135 | — |
| Dana Farber Brigham Cancer Center | Foxborough | Massachusetts | 02035 | — |
| Dana Farber At Milford Regional Cancer Center | Milford | Massachusetts | 01757 | — |
| Dana Farber/Bwcc in Affiliation With South Shore Hospital | South Weymouth | Massachusetts | 02190 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| Regional Cancer Care Associates LLC | Hackensack | New Jersey | 07601 | — |
| North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists- New Hyde Park | New Hyde Park | New York | 11042 | — |
| North Shore Hematology Oncology Associates | Patchogue | New York | 11772 | — |
| North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists | Port Jefferson Station | New York | 11776 | — |
| North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists - Bronx | The Bronx | New York | 10469 | — |
| Texas Oncology, P.A. | McAllen | Texas | 78503 | — |
| Ut Health San Antonio | San Antonio | Texas | 78229 | — |
| Texas Oncology, P.A. | Sugar Land | Texas | 77479 | — |
| Texas Oncology-Tyler | Tyler | Texas | 75702 | — |
| Utah Cancer Specialists IHO Corp | Salt Lake City | Utah | 84106 | — |
| Providence Regional Cancer System | Lacey | Washington | 98503 | — |
| VA Puget Sound Health Care System | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 224 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05555732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05555732 live on ClinicalTrials.gov.